Expansion of warning statement may be considered after submission of first year PSUR data: CDSCO panel on AstraZeneca's anticancer drug
New Delhi: Noting that Tremelimumab Concentrate for Solution for infusion 20 mg/ml is not yet launched in the Indian market, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined that the drug major Astra Zeneca's proposal for the expansion of the warning statement from “To be sold by retail on the prescription of a registered oncologist only” to “To be sold by retail on the prescription of a registered oncologist or gastroenterologist only” may be considered after submission of first-year Periodic Safety Update Report (PSUR) data.
Tremelimumab is an anti-CTLA-4 antibody used to treat unresectable hepatocellular carcinoma in combination with durvalumab.
Tremelimumab is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tumour growth. Because CTLA-4 is an immune checkpoint that plays a vital role in regulating T cell-mediated immune responses, tremelimumab is considered an immune checkpoint inhibitor, which is an emerging cancer immunotherapy drug class.
At the recent SEC meeting on the 5th and 6th of June 2024, the expert panel reviewed the proposal for expansion of the warning statement for the approved drug Tremelimumab Concentrate for Solution for infusion 20 mg/ml (25 mg/1.25 ml and 300 mg/15 ml presentations) in single-dose vials from “To be sold by retail on the prescription of a registered oncologist only” to “To be sold by retail on the prescription of a registered oncologist/ gastroenterologist only”.
After detailed deliberation, the committee recommended,
"The proposal for expansion of the warning statement may be considered after submission of the first-year PSUR data and subsequent review of the same by the committee."
Also Read:Zydus Life Science Gets CDSCO Panel Nod To Manufacture and Market Anti-cancer Drug Nelarabine
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.